Method for preparing contrast preparation based on human serum albumin for visualizing tumour tissues
RU2630672C1
Recombinant of vv-gmcsf / lact-dgf virus of osvovicine, of only-colic activity and producing secretable chimeric white, containing from granulocyte-macrophagal colonistimulating human factor and oncotoxic protein of lactaptin
RU2630658C1
Method of cultivation of amniotic liquid cells
RU2621861C1
RECOMBINANT STRAIN OF VV-GMCSF-S-Lact VACCINIA VIRUS, WITH ONCOLYTIC ACTIVITY, PRODUCING GRANULOCYTOR-MACROPHAGAL COLONY-STIMULATING HUMAN FACTOR AND SECRETED FORM OF LACTAPTIN ONCOTOXIC PROTEIN
RU2619053C1
RECOMBINANT PLASMID pET-15b_T3_RL DNA PROVIDING SYNTHESIS OF RECOMBINANT FUSION PROTEIN CONSISTING OF TUMOR-SPECIFIC PEPTIDES AND ANTITUMOR PEPTIDE RL2, AND RECOMBINANT FUSION PROTEIN POSSESSING ANTI-TUMOR ACTIVITY AGAINST HUMAN BREAST CANCER
RU2619050C1
RECOMBINANT PLASMID pET-15b_T1_RL DNA PROVIDING SYNTHESIS OF RECOMBINANT FUSION PROTEIN CONSISTING OF TUMOR-SPECIFIC PEPTIDES AND ANTITUMOR PEPTIDE RL2, AND RECOMBINANT FUSION PROTEIN POSSESSING CYTOTOXIC ACTIVITY AGAINST CANCER CELLS AND TARGETED PROPERTIES AGAINST TUMOR TISSUE
RU2612890C1
Method for col1a2 gene promoter region methylation level determination for colon cancer diagnosis
RU2612894C1
Method for brca1 and brca2 genes exons nucleotide sequence determination
RU2611362C1
Water-soluble composition, possessing anti-tumour activity and method for obtaining thereof
RU2612256C1
Hydrazine thiazole derivatives of usnic acid with inhibitory action towards human tyrosyl-dna-phosphodiesterase 1 enzyme
RU2595404C1
Tumour-specific peptide for address chemotherapy of human breast cancer
RU2599500C1
Contrast agent for introduction of fluorine-19 label into proteins containing lysine residues
RU2598468C2
Method for evaluating distal oesophagus state after treatment
